Pilgrim Partners Asia Pte Ltd Takes $392,000 Position in Genmab A/S (NASDAQ:GMAB)

Pilgrim Partners Asia Pte Ltd acquired a new stake in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 18,800 shares of the company’s stock, valued at approximately $392,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in shares of Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after purchasing an additional 12,654 shares in the last quarter. FMR LLC lifted its holdings in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares in the last quarter. Verition Fund Management LLC bought a new position in shares of Genmab A/S in the third quarter valued at approximately $709,000. HighTower Advisors LLC purchased a new position in Genmab A/S during the third quarter valued at approximately $273,000. Finally, Quantinno Capital Management LP increased its holdings in Genmab A/S by 56.8% during the 3rd quarter. Quantinno Capital Management LP now owns 24,207 shares of the company’s stock worth $590,000 after acquiring an additional 8,766 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Down 4.4 %

GMAB opened at $18.39 on Friday. Genmab A/S has a 12 month low of $18.30 and a 12 month high of $30.41. The business’s 50-day moving average price is $20.67 and its 200-day moving average price is $21.64. The company has a market cap of $12.17 billion, a P/E ratio of 10.57, a P/E/G ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Truist Financial reduced their price target on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Sanford C. Bernstein lowered shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday. Finally, Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.